Becton, Dickinson and Company (BDX) Insider Trading Activity

NYSE$177.38-0.06 (-0.03%)
Market Cap
$64.29B
Sector
Healthcare
Industry
Medical—Instruments & Supplies
Rank in Sector
151 of 885
Rank in Industry
8 of 49

BDX Insider Trading Activity

BDX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$1,005,743
1
6
Sells
$1,959,768
16
94

Related Transactions

HAYES GREGORYdirector
1
$1.01M
0
$0
$1.01M
SCOTT BERTRAM Ldirector
0
$0
1
$38,318
$-38,318
Feld MichaelEVP & President, Life Sciences
0
$0
6
$76,604
$-76,604
Shan DavidEVP and Chief ISC Officer
0
$0
1
$199,608
$-199,608
Fraser Clairedirector
0
$0
2
$337,892
$-337,892
Byrd RichardEVP & President Interventional
0
$0
2
$541,895
$-541,895
Garrison Michael DavidEVP & President, Medical
0
$0
4
$765,450
$-765,450

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Insider Activity of Becton, Dickinson and Company

Over the last 12 months, insiders at Becton, Dickinson and Company have bought $1.01M and sold $1.96M worth of Becton, Dickinson and Company stock.

On average, over the past 5 years, insiders at Becton, Dickinson and Company have bought $678,086 and sold $4.35M worth of stock each year.

Highest buying activity among insiders over the last 12 months: HAYES GREGORY (director) — $1.01M.

The last purchase of 5,250 shares for transaction amount of $1.01M was made by HAYES GREGORY (director) on 2025‑08‑11.

List of Insider Buy and Sell Transactions, Becton, Dickinson and Company

2026-01-26SaleFeld MichaelEVP, CRO & Pres. Life Sciences
75
<0.0001%
$202.73
$15,205
-0.67%
2026-01-15SaleGarrison Michael DavidEVP & Pres Med.Essntl&BioPharm
1,610
0.0006%
$207.46
$334,005
-2.00%
2025-12-26SaleFeld MichaelEVP, CRO & Pres. Life Sciences
74
<0.0001%
$196.08
$14,510
+3.35%
2025-12-17SaleGarrison Michael DavidEVP & Pres Med.Essntl&BioPharm
629
0.0002%
$196.03
$123,303
+3.41%
2025-12-01SaleFeld MichaelEVP, CRO & Pres. Life Sciences
75
<0.0001%
$193.36
$14,502
+4.71%
2025-11-07SaleSCOTT BERTRAM Ldirector
217
<0.0001%
$176.58
$38,318
+10.62%
2025-10-27SaleFeld MichaelEVP & President, Life Sciences
57
<0.0001%
$186.01
$10,603
+4.85%
2025-09-26SaleFeld MichaelEVP & President, Life Sciences
58
<0.0001%
$181.03
$10,500
+4.86%
2025-09-10SaleFraser Clairedirector
917
0.0003%
$187.50
$171,938
+1.96%
2025-08-22SaleFeld MichaelEVP & President, Life Sciences
57
<0.0001%
$197.99
$11,285
-3.40%
2025-08-11PurchaseHAYES GREGORYdirector
5,250
0.0018%
$191.57
$1.01M
+0.51%
2025-08-08SaleFraser Clairedirector
863
0.0003%
$192.30
$165,955
-0.06%
2025-07-18SaleGarrison Michael DavidEVP & President, Medical
1,185
0.0004%
$180.29
$213,645
+7.66%
2025-06-02SaleShan DavidEVP and Chief ISC Officer
1,166
0.0004%
$171.19
$199,608
+12.91%
2025-04-09SaleGarrison Michael DavidEVP & President, Medical
479
0.0002%
$197.28
$94,497
-8.92%
2025-03-18SaleByrd RichardEVP & President Interventional
459
0.0002%
$230.00
$105,570
-17.11%
2025-03-12SaleByrd RichardEVP & President Interventional
1,940
0.0007%
$224.91
$436,325
-13.92%
2025-02-12SaleSCOTT BERTRAM Ldirector
700
0.0002%
$227.99
$159,593
-13.81%
2025-02-10PurchaseHenderson Jeffrey Williamdirector
1,500
0.0005%
$233.62
$350,430
-15.09%
2025-01-21SaleNeal Shana CarolEVP and Chief People Officer
787
0.0003%
$240.00
$188,880
-18.87%
Total: 421
*Gray background shows transactions not older than one year

Insider Historical Profitability

6.06%
SCOTT BERTRAM Ldirector
35816
0.0099%
$6.36M04
Fraser Clairedirector
22226
0.0061%
$3.94M09
Feld MichaelEVP, CRO & Pres. Life Sciences
16431
0.0045%
$2.92M06
Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm
12095
0.0033%
$2.15M09
Byrd RichardEVP & President Interventional
6952
0.0019%
$1.23M05
HAYES GREGORYdirector
6046
0.0017%
$1.07M10
Shan DavidEVP and Chief ISC Officer
4575
0.0013%
$811,788.0003
FORLENZA VINCENT AChairman of the Board
208864
0.0577%
$37.06M026
LUDWIG EDWARD JChairman
97188
0.0268%
$17.25M039
RING TIMOTHY Mdirector
93688
0.0259%
$16.62M03
CONSIDINE JOHN RVice Chairman
89650
0.0247%
$15.91M07
COHEN GARY MExecutive Vice President
71770
0.0198%
$12.73M021
KOZY WILLIAM AExecutive Vice President
68823
0.019%
$12.21M023
HANSON ALFRED JOHNExecutive Vice President
40273
0.0111%
$7.15M05
Polen Thomas E JrChairman, CEO and President
28878
0.008%
$5.12M010
BECTON HENRY P JRdirector
23820
0.0066%
$4.23M056
ORR JAMES Fdirector
23045
0.0064%
$4.09M03
SHERMAN JEFFREY SSr. VP and General Counsel
22094
0.0061%
$3.92M017
Conroy AlexandreEVP of Integrated Supply Chain
21260
0.0059%
$3.77M08
OVERLOCK WILARD J JRdirector
21091
0.0058%
$3.74M22
+1.25%
Mecklenburg Gary Adirector
20965
0.0058%
$3.72M01
Lim James CExecutive Vice President
19768
0.0055%
$3.51M010
DEGRAAN EDWARDdirector
18608
0.0051%
$3.3M01
ANDERSON BASILdirector
17221
0.0048%
$3.06M01
SOMMER ALFREDdirector
16228
0.0045%
$2.88M05
Neal Shana CarolEVP and Chief People Officer
15414
0.0043%
$2.74M03
Boles Donna MSenior VP - Human Resources
14607
0.004%
$2.59M08
Goette RolandEVP and President, EMEA
14217
0.0039%
$2.52M06
TOZZI WILLIAM AEVP Pres Interventional
13208
0.0036%
$2.34M013
Tharby Linda MExecutive Vice President
11337
0.0031%
$2.01M04
Campion Simon DEVP and Segment President
10773
0.003%
$1.91M02
RIMEL REBECCA Wdirector
10618
0.0029%
$1.88M06
Kaltenbach PatrickEVP & Pres Life Sciences
10340
0.0029%
$1.83M09
UGGLAS MARGERETHA AFdirector
10000
0.0028%
$1.77M10
+22.59%
BURZIK CATHERINE Mdirector
10007
0.0028%
$1.78M31
+5.53%
BEATY HARRY Ndirector
9204
0.0025%
$1.63M01
DURACK DAVID TSenior Vice President
8382
0.0023%
$1.49M022
Mas Ribo AlbertoEVP and Pres, Life Sciences
8381
0.0023%
$1.49M06
Henderson Jeffrey Williamdirector
8015
0.0022%
$1.42M10
SHRADER PATRICIA BSenior Vice President
7915
0.0022%
$1.4M04
Sichak StephenExecutive Vice President
7953
0.0022%
$1.41M011
Shabshab NabilExecutive Vice President
7811
0.0022%
$1.39M05
Bruder Scott PSrVP; Chief Technology Officer
7626
0.0021%
$1.35M01
Strahlman Ellen RSenior Vice President
6037
0.0017%
$1.07M02
Khichi Samrat S.EVP and General Counsel
5928
0.0016%
$1.05M03
Larson Betty DEVP HR & CHRO
5872
0.0016%
$1.04M03
Elkins David VExecutive VP and CFO
5513
0.0015%
$978,226.7201
DAGEVILLE JEAN MARCVP - Human Resources
4658
0.0013%
$826,515.5201
Hickey DavidEVP & President, Life Sciences
4199
0.0012%
$745,070.5604
Minehan Cathy E.director
3000
0.0008%
$532,320.0020
+2.04%
Melcher David Fdirector
2728
0.0008%
$484,056.3210
+8.75%
Borzi James WEVP & Chief Supply Chain Offcr
2775
0.0008%
$492,396.0002
Hurwitz Jerome VExecutive Vice President
3027
0.0008%
$537,110.8804
Gallagher John EVP, Corp Finance and Treasurer
2099
0.0006%
$372,446.5605
Bodner Charles RSVP Corp Fin Chief Acct Office
2037
0.0006%
$361,445.2802
Spoerel Thomas JSVP,Controller&Chief Acct Off
1976
0.0005%
$350,621.4407
*Gray background shows insiders who have made transactions during last year

BDX Institutional Investors: Active Positions

Increased Positions665+35.93%27M+10.05%
Decreased Positions821-44.35%27M-10.09%
New Positions180New3MNew
Sold Out Positions145Sold Out6MSold Out
Total Postitions1,695-8.43%267M-0.04%

BDX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$6.33M11.39%32.46M+147,041+0.46%2025-09-30
Blackrock, Inc.$5.41M9.74%27.75M+472,432+1.73%2025-09-30
T. Rowe Price Investment Management, Inc.$3.16M5.7%16.23M+54,113+0.33%2025-09-30
State Street Corp$2.7M4.87%13.87M+459,219+3.42%2025-09-30
First Eagle Investment Management, Llc$1.95M3.51%9.99M+1M+13.75%2025-09-30
Massachusetts Financial Services Co /Ma/$1.78M3.21%9.15M+636,138+7.47%2025-09-30
Geode Capital Management, Llc$1.33M2.4%6.83M+107,775+1.6%2025-09-30
Franklin Resources Inc$1.31M2.36%6.74M+4M+150.85%2025-09-30
Jpmorgan Chase & Co$1.03M1.86%5.29M+743,678+16.37%2025-09-30
Wellington Management Group Llp$1.02M1.84%5.23M+5M+9,056.29%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.